TC Biopharm Stock (NASDAQ:TCBP)
Previous Close
$0.50
52W Range
$0.08 - $523.20
50D Avg
$3.18
200D Avg
$48.27
Market Cap
$256.50K
Avg Vol (3M)
$377.72K
Beta
0.01
Div Yield
-
TCBP Company Profile
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.